{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:00Z","timestamp":1793665980440,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10384-017-0524-y","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T02:28:13Z","timestamp":1498444093000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits"],"prefix":"10.1007","volume":"61","author":[{"given":"Yusuke","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Takaseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"524_CR1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/bjo.80.5.389","volume":"80","author":"HA Quigley","year":"1996","unstructured":"Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389\u201393.","journal-title":"Br J Ophthalmol"},{"key":"524_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The advanced glaucoma intervention study","year":"2000","unstructured":"The advanced glaucoma intervention study. (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"524_CR3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bjo.79.8.732","volume":"79","author":"Y Yamazaki","year":"1995","unstructured":"Yamazaki Y, Hayamizu F. Comparison of flow velocity of ophthalmic artery between primary open angle glaucoma and normal tension glaucoma. Br J Ophthalmol. 1995;79:732\u20134.","journal-title":"Br J Ophthalmol"},{"key":"524_CR4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00417-005-0177-2","volume":"244","author":"EA Sato","year":"2006","unstructured":"Sato EA, Ohtake Y, Shinoda K, Mashima Y, Kimura I. Decreased blood flow at neuroretinal rim of optic nerve head corresponds with visual field deficit in eyes with normal tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:795\u2013801.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"524_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1350-9462(02)00008-3","volume":"21","author":"J Flammer","year":"2002","unstructured":"Flammer J, Org\u00fcl S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21:359\u201393.","journal-title":"Prog Retin Eye Res"},{"key":"524_CR6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.exer.2010.09.004","volume":"91","author":"H Kurashima","year":"2010","unstructured":"Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin F2\u03b1 analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91:853\u20139.","journal-title":"Exp Eye Res"},{"key":"524_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/112067210101100108","volume":"11","author":"R Altan-Yaycioglu","year":"2001","unstructured":"Altan-Yaycioglu R, T\u00fcrker G, Akd\u00f6l S, Acuna\u015f G, Izgi B. The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color doppler imaging study. Eur J Ophthalmol. 2001;11:37\u201346.","journal-title":"Eur J Ophthalmol"},{"key":"524_CR8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.survophthal.2008.06.002","volume":"54","author":"B Siesky","year":"2009","unstructured":"Siesky B, Harris A, Brizendine E, Marques C, Loh J, Mackey J, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol. 2009;54:33\u201346.","journal-title":"Surv Ophthalmol"},{"key":"524_CR9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archopht.119.8.1171","volume":"119","author":"M Honjo","year":"2001","unstructured":"Honjo M, Inatani M, Kido N, Sawamura T, Yue BY, Honda Y, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119:1171\u20138.","journal-title":"Arch Ophthalmol"},{"key":"524_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/02713680802531353","volume":"34","author":"T Fukunaga","year":"2009","unstructured":"Fukunaga T, Ikesugi K, Nishio M, Sugimoto M, Sasoh M, Hidaka H, et al. The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading. Curr Eye Res. 2009;34:42\u20137.","journal-title":"Curr Eye Res"},{"key":"524_CR11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/02713680902783763","volume":"34","author":"M Nishio","year":"2009","unstructured":"Nishio M, Fukunaga T, Sugimoto M, Ikesugi K, Sumi K, Hidaka H, et al. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes. Curr Eye Res. 2009;34:282\u20136.","journal-title":"Curr Eye Res"},{"key":"524_CR12","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"524_CR13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288\u201395.","journal-title":"JAMA Ophthalmol"},{"key":"524_CR14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, et al. Phase 2 randomized clinical study of a rho kinase inhibitor, k-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"524_CR15","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211\u20135.","journal-title":"Drugs."},{"key":"524_CR16","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254\u201360.","journal-title":"Acta Ophthalmol"},{"key":"524_CR17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol"},{"key":"524_CR18","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"},{"key":"524_CR19","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, Kido N, Yue BY, Narumiya S, et al. Effect of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"524_CR20","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci Rep. 2016;6:19640.","journal-title":"Sci Rep"},{"key":"524_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pneurobio.2015.06.002","volume":"131","author":"S Velde Van de","year":"2015","unstructured":"Van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I. Towards axonal regeneration and neuroprotection in glaucoma: rho kinase inhibitors as promising therapeutics. Prog Neurobiol. 2015;131:105\u201319.","journal-title":"Prog Neurobiol"},{"key":"524_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","volume":"37","author":"T Inoue","year":"2013","unstructured":"Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1\u201312.","journal-title":"Prog Retin Eye Res"},{"key":"524_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.tips.2007.04.006","volume":"28","author":"H Shimokawa","year":"2007","unstructured":"Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296\u2013302.","journal-title":"Trends Pharmacol Sci"},{"key":"524_CR24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2337\/db07-1241","volume":"57","author":"V Kolavennu","year":"2008","unstructured":"Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA\/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008;57:714\u201323.","journal-title":"Diabetes"},{"key":"524_CR25","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/01.STR.0000181077.84981.11","volume":"36","author":"Y Rikitake","year":"2005","unstructured":"Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005;36:2251\u20137.","journal-title":"Stroke"},{"key":"524_CR26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/TCRM.S2907","volume":"4","author":"T Kubo","year":"2008","unstructured":"Kubo T, Yamaguchi A, Iwata N, Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag. 2008;4:605\u201315.","journal-title":"Ther Clin Risk Manag"},{"key":"524_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/jpet.106.110635","volume":"320","author":"C Doe","year":"2007","unstructured":"Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007;320:89\u201398.","journal-title":"J Pharmacol Exp Ther"},{"key":"524_CR28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10384-011-0048-9","volume":"55","author":"H Watabe","year":"2011","unstructured":"Watabe H, Abe S, Yoshitomi T. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries. Jpn J Ophthalmol. 2011;55:411\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"524_CR29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.exer.2014.02.004","volume":"121","author":"H Zhang","year":"2014","unstructured":"Zhang H, Yang D, Ross CM, Wigg JP, Pandav S, Crowston JG. Validation of rebound tonometry for intraocular pressure measurement in the rabbit. Exp Eye Res. 2014;121:86\u201393.","journal-title":"Exp Eye Res"},{"key":"524_CR30","first-page":"1171","volume":"5","author":"N Aizawa","year":"2011","unstructured":"Aizawa N, Yokoyama Y, Chiba N, Omodaka K, Yasuda M, Otomo T, et al. Reproducibility of retinal circulation measurements obtained using laser speckle flowgraphy-NAVI in patients with glaucoma. Clin Ophthalmol. 2011;5:1171\u20136.","journal-title":"Clin Ophthalmol"},{"key":"524_CR31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1755-3768.2009.01586.x","volume":"88","author":"T Sugiyama","year":"2010","unstructured":"Sugiyama T, Araie M, Riva CE, Schmetterer L, Orgul S. Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol. 2010;88:723\u20139.","journal-title":"Acta Ophthalmol"},{"key":"524_CR32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s10384-006-0377-2","volume":"50","author":"Y Dong","year":"2006","unstructured":"Dong Y, Ishikawa H, Wu Y, Shimizu K, Goseki T, Yoshitomi T. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Jpn J Ophthalmol. 2006;50:504\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"524_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.exer.2007.01.010","volume":"84","author":"Y Dong","year":"2007","unstructured":"Dong Y, Ishikawa H, Wu Y, Yoshitomi T. Vasodilatory mechanism of levobunolol on vascular smooth muscle cells. Exp Eye Res. 2007;84:1039\u201346.","journal-title":"Exp Eye Res"},{"key":"524_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.exer.2008.06.005","volume":"87","author":"Y Dong","year":"2008","unstructured":"Dong Y, Watabe H, Su G, Ishikawa H, Sato N, Yoshitomi T. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res. 2008;87:251\u20136.","journal-title":"Exp Eye Res"},{"key":"524_CR35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1113\/jphysiol.1978.sp012179","volume":"275","author":"W Halpern","year":"1978","unstructured":"Halpern W, Mulvany MJ, Warshaw DM. Mechanical properties of smooth muscle cells in the walls of arterial resistance vessels. J Physiol. 1978;275:85\u2013101.","journal-title":"J Physiol"},{"key":"524_CR36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/260617a0","volume":"260","author":"MJ Mulvany","year":"1976","unstructured":"Mulvany MJ, Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature. 1976;260:617\u20139.","journal-title":"Nature"},{"key":"524_CR37","first-page":"H1096","volume":"257","author":"KD Keef","year":"1989","unstructured":"Keef KD, Bowen SM. Effect of ACh on electrical and mechanical activity in guinea pig coronary arteries. Am J Physiol. 1989;257:H1096\u2013103.","journal-title":"Am J Physiol"},{"key":"524_CR38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.exer.2009.11.009","volume":"90","author":"Y Dong","year":"2010","unstructured":"Dong Y, Watabe H, Cui J, Abe S, Sato N, Ishikawa H, et al. Reduced effects of endothelium-derived hyperpolarizing factor in ocular ciliary arteries from spontaneous hypertensive rats. Exp Eye Res. 2010;90:324\u20139.","journal-title":"Exp Eye Res"},{"key":"524_CR39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-2999(87)90563-2","volume":"141","author":"PJA Hutchinson","year":"1987","unstructured":"Hutchinson PJA, Palmer RMJ, Moncada S. Comparative pharmacology of EDRF and nitric oxide on vascular strips. Eur J Pharmacol. 1987;141:445\u201351.","journal-title":"Eur J Pharmacol"},{"key":"524_CR40","first-page":"213","volume":"11","author":"PM Vanhoutte","year":"1986","unstructured":"Vanhoutte PM. The endothelium and arterial reactivity. J Mal Vasc. 1986;11:213\u201321.","journal-title":"J Mal Vasc"},{"key":"524_CR41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.bjp.0703175","volume":"129","author":"JF Quignard","year":"2000","unstructured":"Quignard JF, Feletou M, Edwards G, Duhault J, Weston AH, Vanhoutte PM. Role of endothelial cell hyperpolarization in EDHF-mediated responses in the guinea-pig carotid artery. Br J Pharmacol. 2000;129:1103\u201312.","journal-title":"Br J Pharmacol"},{"key":"524_CR42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"524_CR43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1167\/iovs.10-5265","volume":"52","author":"T Sugiyama","year":"2011","unstructured":"Sugiyama T, Shibata M, Kajiura S, Okuno T, Tonari M, Oku H, et al. Effects of Fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci. 2011;52:64\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"524_CR44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.exer.2015.07.008","volume":"139","author":"S Nakabayashi","year":"2015","unstructured":"Nakabayashi S, Kawai M, Yoshioka T, Song YS, Tani T, Yoshida A, et al. Effect of intravitreal Rho kinase inhibitor ripasudil (K-115) on feline retinal microcirculation. Exp Eye Res. 2015;139:132\u20135.","journal-title":"Exp Eye Res"},{"key":"524_CR45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/eye.2008.142","volume":"23","author":"J Takayama","year":"2009","unstructured":"Takayama J, Mayama C, Mishima A, Nagahara M, Tomidokoro A, Araie M. Topical phenylephrine decreases blood velocity in the optic nerve head, increases resistive index in the retinal arteries. Eye. 2009;23:827\u201334.","journal-title":"Eye."},{"key":"524_CR46","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1167\/iovs.10-5218","volume":"51","author":"C Mayama","year":"2010","unstructured":"Mayama C, Ishii K, Saeki T, Ota T, Tomidokoro A, Araie M. Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest Ophthalmol Vis Sci. 2010;51:4117\u201324.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"524_CR47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39:813\u201322.","journal-title":"Curr Eye Res"},{"key":"524_CR48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/jop.2016.0028","volume":"32","author":"T Isobe","year":"2016","unstructured":"Isobe T, Kasai T, Kawai H. Ocular penetration and pharmacokinetics of ripasudil following topical administration to rabbits. J Ocul Pharmacol Ther. 2016;32:405\u201314.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-017-0524-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-017-0524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-017-0524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T21:40:57Z","timestamp":1569534057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-017-0524-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1007\/s10384-017-0524-y","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]}}}